[Frontiers in Bioscience 17, 1775-1794, January 1, 2012]

RHAMM and CD44 peptides-analytic tools and potential drugs

Eva A. Turley1, David Naor2

1London Regional Cancer Center, University of Western Ontario, London, ON, Canada N6A 4L6, 2The Lautenberg Center for General and Tumor Immunology, Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel


1. Abstract
2. Introduction
3. CD44: structure and function
4. CD44 peptides derived from the CD44 receptor
5. The Trojan horse CD44-derived peptide
6. HA binding peptide derived from phage-display library (Pep-1)
7. Blocking peptides derived from CD44 ligands
8. RHAMM: structure and function
9. RHAMM peptides used as vaccines
10. RHAMM peptides that alter wound repair
11. Use of RHAMM peptides in cancer and arthritis
12. Development of RHAMM binding peptides as HA mimetic peptides
13. Conclusions
14. Acknowledgements
15. References


CD44 and RHAMM are two extracellar matrix receptors whose principle ligand is the polysaccharide hyaluronan (HA). Both proteins are involved in wound repair and their aberrant regulation contributes to a variety of diseases including arthritis and cancer. Over the past decade, a number of peptide-based therapeutics that block the binding of CD44 or RHAMM-specific ligands have been developed and tested in experimental models of disease. Here, we review the structure of each of these proteins, the functions they control and the mechanisms, including their interactions with each other, responsible for these functions. We also review the development of peptide mimics that block the key functions of CD44 and RHAMM and their use in experimental models of disease.